| pubmed-article:17055073 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17055073 | lifeskim:mentions | umls-concept:C0949945 | lld:lifeskim |
| pubmed-article:17055073 | lifeskim:mentions | umls-concept:C0598312 | lld:lifeskim |
| pubmed-article:17055073 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:17055073 | lifeskim:mentions | umls-concept:C1741118 | lld:lifeskim |
| pubmed-article:17055073 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17055073 | pubmed:dateCreated | 2007-2-20 | lld:pubmed |
| pubmed-article:17055073 | pubmed:abstractText | We report on the potent and selective in vitro antiviral activity of 2'-C-methylcytidine (2'-C-MetCyt) against foot-and-mouth disease virus (FMDV). FMDV belongs to the Picornaviridae and has the potential to cause devastating epidemics in livestock. The 50% and 90% effective concentrations (EC50 and EC90) for inhibition of the FMDV-induced cytopathic effect (CPE) formation were 6.4+/-3.8 and 10.8+/-5.4 microM. Comparable EC50 values for inhibition of viral RNA synthesis were observed. Treatment of FMDV-infected BHK-21 cells with 77 microM 2'-C-MetCyt resulted in a (1.6-3.2)x10(3)-fold reduction of infectious virus yield. Time-of-drug addition experiments suggest that 2'-C-MetCyt interacts with viral replication at a time point that coincides with the onset of intracellular viral RNA synthesis. In contrast to emergency vaccination, a potent and selective antiviral agent may provide almost immediate (prophylactic/therapeutic) protection against infection and thus constitute an important alternative/supplementary option to contain outbreaks such as those caused by FMDV. | lld:pubmed |
| pubmed-article:17055073 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17055073 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17055073 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17055073 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17055073 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17055073 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17055073 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17055073 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17055073 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:17055073 | pubmed:issn | 0166-3542 | lld:pubmed |
| pubmed-article:17055073 | pubmed:author | pubmed-author:ToussaintJean... | lld:pubmed |
| pubmed-article:17055073 | pubmed:author | pubmed-author:NeytsJohanJ | lld:pubmed |
| pubmed-article:17055073 | pubmed:author | pubmed-author:GorisNesyaN | lld:pubmed |
| pubmed-article:17055073 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:17055073 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:17055073 | pubmed:author | pubmed-author:MuschInaI | lld:pubmed |
| pubmed-article:17055073 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17055073 | pubmed:volume | 73 | lld:pubmed |
| pubmed-article:17055073 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17055073 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17055073 | pubmed:pagination | 161-8 | lld:pubmed |
| pubmed-article:17055073 | pubmed:meshHeading | pubmed-meshheading:17055073... | lld:pubmed |
| pubmed-article:17055073 | pubmed:meshHeading | pubmed-meshheading:17055073... | lld:pubmed |
| pubmed-article:17055073 | pubmed:meshHeading | pubmed-meshheading:17055073... | lld:pubmed |
| pubmed-article:17055073 | pubmed:meshHeading | pubmed-meshheading:17055073... | lld:pubmed |
| pubmed-article:17055073 | pubmed:meshHeading | pubmed-meshheading:17055073... | lld:pubmed |
| pubmed-article:17055073 | pubmed:meshHeading | pubmed-meshheading:17055073... | lld:pubmed |
| pubmed-article:17055073 | pubmed:meshHeading | pubmed-meshheading:17055073... | lld:pubmed |
| pubmed-article:17055073 | pubmed:meshHeading | pubmed-meshheading:17055073... | lld:pubmed |
| pubmed-article:17055073 | pubmed:meshHeading | pubmed-meshheading:17055073... | lld:pubmed |
| pubmed-article:17055073 | pubmed:meshHeading | pubmed-meshheading:17055073... | lld:pubmed |
| pubmed-article:17055073 | pubmed:meshHeading | pubmed-meshheading:17055073... | lld:pubmed |
| pubmed-article:17055073 | pubmed:meshHeading | pubmed-meshheading:17055073... | lld:pubmed |
| pubmed-article:17055073 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17055073 | pubmed:articleTitle | 2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. | lld:pubmed |
| pubmed-article:17055073 | pubmed:affiliation | Department of Virology, Epizootic Diseases Section, Veterinary and Agrochemical Research Centre, Groeselenberg 99, 1180 Brussels, Belgium. negor@var.fgov.be | lld:pubmed |
| pubmed-article:17055073 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17055073 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17055073 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17055073 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17055073 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17055073 | lld:pubmed |
